Boston Scientific Gaining Patent Muscle Through $2.1 Bil. Schneider Buy
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's planned $2.1 bil. cash acquisition of Pfizer's Schneider division comes at a particularly opportune time for BSC, with the deal expected to close around the time the firm is expected to gain FDA approval to sell a rapid-exchange version of its NIR coronary stent.